EQUASENS: Q1 2023 revenue: +13.96% to €56.25m
11 Mayo 2023 - 11:00AM
EQUASENS: Q1 2023 revenue: +13.96% to €56.25m
Villers-lès-Nancy, 11 May 2023 - 6:00 p.m.
(CET)
PRESS RELEASE
Q1 2023 revenue:
+13.96% to €56.25m
- Growth by all
Divisions (except FINTECH, still affected
by higher interest rates).
- Continuing deployment and
installation of solutions in phase 1 of the
SEGUR French Digital Healthcare
investment programme: Q1 2023 revenue of €1.43m.
- 2023
Group outlook:
- A
service and technology offering strengthened by recent
acquisitions: ATOOPHARM, PRATILOG and
SPEECH2SENSE.
-
Growth targets
confirmed.
In €m |
Q1 2022 |
Q1 2023 * |
Change |
Revenue |
49.36 |
56.25 |
+ 13.96% |
* Unaudited
****
Operating highlights
While the consolidation scope remains unchanged
in relation to Q1 2022, organisational changes were made
between Divisions to streamline business activities:
- after buying out
the minority interests, MULTIMEDS and I-MEDS were transferred to
the PHARMAGEST Division (Compliance segment) and CAREMEDS joined
the AXIGATE LINK Division (Nursing Home segment);
- ICT which addresses
the segment of primary care physicians with its solutions MEDILINK
(for health centres and regional health professional communities)
and INFILINK (for IDELs) joined the MEDICAL SOLUTIONS Division
(formerly MEDICAL SOFT) to complete the business offering of PROKOV
EDITIONS (MédiStory software for general practitioners and
specialists).
- The
PHARMAGEST Division registered strong sales growth in all
its business lines and geographical markets: €42.35m, up 16.25%
from Q1 2022. The Division accounts for 75.28% of Equasens
Group revenue (compared to 73.80% in 2022).
- Sales of new
configurations increased significantly, driven in particular by a
very dynamic e-label market in France and new software solutions in
Italy.
- License sales are
also on the rise with the success of new offerings, and in
particular for messaging, mobility and backup solutions.
- The AXIGATE
LINK Division had revenue of €7.23m, up 7.10% from
Q1 2022. The Division accounts for 12.85% of Equasens Group
revenue (compared to 13.67% in 2022).
- All the Division’s
Business Units (nursing homes, hospital-at-home programmes,
hospitals, telemedicine) contributed to this performance, bolstered
by SEGUR programme functionalities in the nursing home and
hospital-at-home segments.
- The MEDICAL
SOLUTIONS Division had revenue of 2.23m, up 24.22%
from Q1 2022. The Division accounts for 3.97% of Equasens
Group revenue (compared to 3.64% in 2022).
- This Division
henceforth covers software solutions for physicians and health
centres provided by PROKOV EDITIONS and ICT respectively.
- Its growth has in
large part benefited from the success of the new version of
MédiStory (the first medical practice management software to be
approved by the SEGUR programmer in May 2022).
- The
E-CONNECT Division had revenue of 3.98m, up 3.10%
from Q1 2022. The Division accounts for 7.08% of Equasens
Group revenue (compared to 7.83% in 2022).
- Reflecting efforts
to diversify production sources which began at the end of 2022, its
capacity was restored in March in line with market
expectations.
- The FINTECH
Division had revenue of €0.46m, down 11.80% from
Q1 2022. The Division accounts for 0.82% of Equasens Group
revenue (compared to 1.06% in 2022).
- Revenue remained in
line with the trend of 2022 as the financing sector continues to be
adversely impacted by high interest rates.
Significant events occurring after 31
March 2023
In early April, Equasens Group announced the
completion of three acquisitions:
- The MEDICAL
SOLUTIONS Division was reinforced by the addition of PRATILOG and
SPEECH2SENSE which will contribute to growth in market share for
software solutions in the medical and nursing segments and
expansion into the physiotherapy segment. With these acquisitions,
the Group's portfolio of software solutions now includes proven
applications and an innovative medical speech recognition
technology that will enhance its product offering and add value to
its business applications.
- ATOOPHARM, the
specialist in e-learning solutions for retail pharmacies, joined
the PHARMAGEST Division. The Group has in this way completed its
global offering to accompany healthcare professionals in the
transformation of their activities, as an integrated provider of
software and applications, connected equipment, financing and
training.
2023 outlook
Boosted by its latest acquisitions, the Group
intends to maintain its trajectory of organic growth in line with
this performance in Q1 and confirms its full-year targets for
2023.
Financial calendar
-
29/06/2023: Annual Ordinary
General Meeting.
- Equasens Group will
propose at the Annual General Meeting the payment of a dividend of
€ 1.15 per share for fiscal 2022.
- The General Meeting
will be held at the registered office in Villers-lès-Nancy.
Shareholders are invited to regularly consult the section devoted
to the General Meeting on its website www.equasens.com – Section
Investisseurs / Assemblée Générale for information about the
procedures for participation.
-
03/08/2023: H1 2023 revenue (after the close
of trading).
- 29/09/2023: H1 2023
results (after the close of trading).
- 02/10/2023: H1 2023
results presentation (by video
conference).
About Group Equasens
Founded more than 35 years ago, Equasens Group,
which now has more than 1,200 employees in Europe, is the leading
publisher of software solutions for the healthcare industry in
terms of the diversity of its business applications and market
share.
Equasens Group’s specialised business
applications facilitate the day-to-day work of healthcare
professionals and their teams, working in private practice,
collaborative medical structures or healthcare establishments. The
Group also provides comprehensive support to healthcare
professionals in the transformation of their profession by
developing electronic equipment, digital solutions and healthcare
robotics, as well as financing and training adapted to their
specific needs.
And reflecting the spirit of its tagline "
technology for a more human experience", the Group is a leading
provider of interoperability solutions that improve coordination
between healthcare professionals, their communications and data
exchange resulting in better patient care and a more efficient
healthcare system.
Listed on Euronext Paris™ - Compartment
AIndexes: MSCI GLOBAL SMALL CAP - GAÏA Index 2020 - CAC®
SMALL and CAC® All-TradableIncluded in the Euronext Tech Leaders
segment and the European Rising Tech label
Eligible for the Deferred Settlement Service
(“Service à Règlement Différé” - SRD) and equity savings accounts
invested in small and mid caps (PEA-PME)ISIN: FR 0012882389 –
Ticker Code: EQS
Get all the news about the Equasens
Group www.equasens.com and
on LinkedIn
CONTACTS
Analyst and
Investor Relations: Chief Administrative and Financial
Officer: Frédérique SCHMIDTTel. +33 (0)3 83 15 90 67 -
frederique.schmidt@equasens.com
Media
Relations: FIN’EXTENSO - Isabelle APRILETel. +33 (0)6
17 38 61 78 - i.aprile@finextenso.fr
- EQUASENS_PRESSRELEASE_20230511_Q1 2023 REVENUE_en_US
Equasens (LSE:0R9T)
Gráfica de Acción Histórica
De Abr 2024 a May 2024
Equasens (LSE:0R9T)
Gráfica de Acción Histórica
De May 2023 a May 2024